	US 11,899,025 B2
	Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising COX2 acetylating agent as active ingredient
Jae-Sung Bae, Daegu (KR); Hee Kyung Jin, Daegu (KR); Ju Youn Lee, Daegu (KR); and Seung Hoon Han, Daegu (KR)
Assigned to KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
Appl. No. 16/982,494
Filed by KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
PCT Filed Mar. 21, 2019, PCT No. PCT/KR2019/003283 § 371(c)(1), (2) Date Sep. 18, 2020, PCT Pub. No. WO2019/182370, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 10-2018-0032669 (KR), filed on Mar. 21, 2018.
Prior Publication US 2021/0003594 A1, Jan. 7, 2021
Int. Cl. G01N 33/68 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01); A61K 31/164 (2006.01)

CPC G01N 33/6896 (2013.01) [A61K 31/164 (2013.01); G01N 33/5008 (2013.01); G01N 33/573 (2013.01); G01N 2333/90241 (2013.01); G01N 2440/10 (2013.01)]

5 Claims

1. A method of screening an agent for treating Alzheimer's disease, the method comprising the following steps of:

(a) treating cells expressing SphK1 (sphingosine kinase 1) mRNA or protein with a test substance;

(b) measuring the expression level of the SphK1 mRNA or protein in the cells treated with the test substance and cells not treated with the test substance;

(c) selecting a substance that has increased the expression level of the SphK1 mRNA or protein compared to the cells not treated with the test substance;

(d) treating cells expressing COX2 (cyclooxygenase-2) protein with the test substance selected in the step (c);

(e) measuring the degree of acetylation of the COX2 in the cells treated with the test substance and the cells not treated with the test substance; and

(f) selecting a substance having an increased degree of acetylation of the COX2 protein as compared to cells not treated with the test substance as an agent for treating Alzheimer's disease.